跳至主要内容
临床试验/NL-OMON46537
NL-OMON46537撤回不适用

A Multi-Center InternatiONal Registry to Evaluate the Efficacy oF Imaging with Opto-acoustics to Diagnose BrEast CaNCEr - CONFIDENCE-01

Seno Medical Instruments, Inc.0 个研究点目标入组 150 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Have been informed of the nature of the registry and provided written informed consent, prior to initiation of any registry activities,
  • 2. Are males or females 18 years of age or older at the time of consent,
  • 3. Either have a BI-RADS 1 mammogram (50 subjects) or have been referred for a breast ultrasound because of a breast mass/finding found (2100 subjects) on at least one of the following examinations:
  • a. Physical palpation or other signs symptoms (i.e. nipple discharge, skin changes, inflammation, etc.),
  • b. Screening or diagnostic mammography (including 2D mammography or tomosynthesis, CESM),
  • c. Supplemental screening ultrasound exam and/or CDU,
  • d. Screening or diagnostic breast MRI,
  • e. Screening or diagnostic molecular breast imaging (MBI technetium 99m sestamibi scans of the breast),
  • f. Screening or diagnostic PET/CT or PEM,
  • 4. Be willing and able to complete all procedures and assessments in accordance with the
  • clinical protocol,
  • 5. Have up to 3 target mass(es) total per subject.

排除标准

  • 1. Have a condition or impediment that could interfere with the intended field of view (within one probe length or 4 cm of the mass),
  • 2. Mass(es) not visible under screening or diagnostic ultrasound (includes Imagio IUS)
  • 3. Are pregnant,
  • 4. Have open sores including insect bites, rash, poison ivy, and chafing on the skin of the ipsilateral breast within one probe length or 4 cm of each mass to be included,
  • 5. Are experiencing photo-toxicity or photo-sensitivity or are undergoing treatment for a photosensitive condition such as porphyria or lupus erythematosus,
  • 6. Have received or are receiving chemotherapy for any type of cancer up to 90 days prior to the date of the baseline Imagio procedure,
  • 7. Have previously participated in this registry,
  • 8. Are currently enrolled in another investigational study or registry that would directly interfere with the current registry.

研究者

相似试验